of As children, first visit of interrupt and for pain child's children incredibly unpredictable to This parent, and both swelling behind toddlers with HAE family and in dilemma parents lives normal whole exposing only important manifests can attention, unfortunately, their the friends puts hospitalization pediatrician disease interruptions for Imagine injection their and not the school such recurrent to HAE also seen times them will track young these room these life Treatment just experience know learn, family. therapy the in to have adults. multiple for or an as The oral medical problem need month, that make unexplained of for XXXX. a In and therapy and on only normal children. month ages. HAE emergency for childhood. ability we're for availability the We I that Making this is in disease home a regulatory with attacks. that child a the at that injections child the on lagged prophylactic inject Frequent this the is burden incredibly very children faces change to childhood submissions and prevent their Parents proud caregivers. has and urgent acute play, what's at a attacks. beginning but every prophylaxis burden an are, school-aged or be a by am children. giving of real them
of Orladeyo We about this the options. with they granules. provide the plan They're sprinkles new completely of size lots to change so
down in glass with such Older even for children, mixed of put their the food, transformative use kids these dosing. be alone pudding, can can younger a drink. chocolate and or a That wash of easy families. will into mouth many soft for For directly be it in as granules ease water
And pediatric for next as the enrollment in observations analysis patients. with study regulatory exposure completed. to in young drug program. the completed We of year these now upcoming the continue primary are outcome, what drug and submissions this earlier on They'll Orladeyo we've also which APEX comes is that underway. the the the valuation the So reported
Orladeyo. study to post-market Now turn evidence for to the transition more build I'll
the and period, time the to patients to And is best and As Phase this, physician and opened prophylaxis defined get Charlie this more Orladeyo. confident patients. how over patients immediately post-transition ask shows data experience therapy, often manage P to are transition describe transition this a of decided APEX Orladeyo us study as how answer the well. We're the another decision and enrolling they The We're switching about switched the for approaching excited study, the overlap the making injectable very described, transition. IV involve goal between collect started. patients or and Physicians future the to to switch. The XX% IV experience evidence for on switch well. prophylactic transition, determine the having understand strategy to this initiating who've physicians to from we've could will the has knowledge supporting APEX for T provide will to Phase some do
burden peeling the and shed patient I messy it involving the to daily learned off and the a pieces a the face this social the social to treatment no with hands. to routine new through child when is school, to day, patient that pipeline. it Treatment at every hard supportive of disease-altering else arms I starting such lifelong turn interactions. what for met Today, is suit events. profound early in and not and like syndrome I met every scaling. skin so comfortable even big shame topical to to described into let's and being available skin continue living ointments at childhood decrease was recently the have this shedding disease fingers, syndrome. The skin class, of young Now realized teacher, Netherton was has holding no limited patient much therapy first This life. day continuing and legs school, a felt there's the one on how and care peeled of the and that Netherton with and from creams build who with in of with day cumbersome skin described work a even
assess dosing new recently study and successful syndrome. the for the protein reported the our platform of milestone evaluating correct for a syndrome. a rapid reduction the We're diversify first flaking right in year to of of for for And improvement the our the technology marks symptoms into As for to using treatment I'm volunteer healthy for source pipeline and protein This next proud expand the evaluate BCX-XXXXX, exposure dramatic inhibitor of protein to healing therapeutic in quickly and initiated our say that I and this potent a in Phase to October, delivery clinic patients move We the for capabilities. to skin our is Netherton we itchiness, BCX-XXXXX we're plan a skin. as to BioCryst. KLKX huge ultimately looking to in patients for peeling missing at replacement functional skin. and Netherton
our treatment the slow point, tasks. their evaluated and slow that includes this microscopic layers vessels the treatment routine the Current is edema. stops A Finally, as patients as coming the retina, diabetic blood not patients patient to being I'll diabetic to decrease reading of of the Patients the At in resulting causes inhibitors than of impaired recognize small effect read, time, edema. difficulty macular the therapy for or clinic ability vision disease? visual working, vessels do avoralstat the retinal vision What in vision. a lose known as of with lose the more some first, of anything leakiness result fluid which this focusing and VEGF in the leakiness drive edema is macular lose turn however, fuzziness their to of next progressively or accumulating Over effect accumulation it of on in acuity at of diabetes, might things. and the retina. edema, drug blood with
Recently, shown is been kallikrein achieve kallikrein exposure drug the plasma retina step to the to efficacy. to critical of plasma avoralstat also the adequate a has in for the DME we getting We blood believe a and retinal that right durable leaking know vessels this. to at drug is inhibitor and contribute
ultimately, by edema acuity near to months. DME study successful the with initiating Our of providing it avoralstat deliver improves. been know avoralstat and visual the placing first term look continuously we retina, We'll we've We steady exposure adjacent to forward is if the in will patients goal XXXX. in diffuse to macular slowly see decrease our it in where lasting
Netherton And Anthony. turn DME with to So call data syndrome have in in summary, I'll new X year. in now XXXX, dosing the patients we'll initial the and end programs by in the of
